
Lecture 1: 9:15 - 10:15 a.m. CDT


William Polonsky, PhD, CDCES, Presents:

Understanding and Addressing Problematic Adherence to Oral and Injectable Cardiometabolic Medications




The Key Behavioral Contributor to Glycemic Control


Model 1: all self-care behaviours β	Model 2: all self-care behaviours + covariates β			
0.04	0.06			
-0.06	-0.04			
-0.10^{a}	-0.03			
0.03	-0.002			
-0.14^{b}	-0.16^{b}			
	self-care behaviours β 0.04 -0.06 -0.10 ^a 0.03			




WHY AREN'T WE SEEING DRAMATIC IMPROVEMENTS?




Understanding and Addressing Problematic Adherence







Understanding and Addressing Problematic Adherence


POOR ADHERENCE IS THE KEY






Adherence Rates for T2D Agents







INTERVENTION STRATEGIES TO ADDRESS MEDICATION ADHERENCE

- Written medication instructions
- Enhancing HCP adherence skills
- Goal setting
- · Stimuli/prompts to take medications
- · Enhancing support from significant others
- Special packaging of medications
- · Self-monitoring of medication adherence
- · Habit analysis and intervention

Conn and Rupar, 2017

INTERVENTION STRATEGIES TO ADDRESS MEDICATION ADHERENCE

- · Medication side effect management
- · Feedback about medication adherence
- Medication calendars
- · Enhancing patient self-management skills
- Providing consequences/rewards for adherence
- Motivational interviewing
- Stress management

Conn and Rupar, 2017

EFFECTIVENESS OF CURRENT INTERVENTION STRATEGIES

<u>Review of 771 RCTs</u> indicate that effects are modest (Cohen's d):

- Overall: 0.29
- Behavioral strategies:
- Addressing habits:
- No behavioral strategies:

"Much room remains for improvement."

Conn and Ruppar, 2017

0.33

0.37

0.28

WHAT ARE WE MISSING?




THE PROBLEM: FORGETFULNESS?



Understanding and Addressing Problematic Adherence

THE SOLUTION: ADDRESS FORGETFULNESS?





The NEW ENGLAND JOURNAL of MEDICINE

MEDICINE AND SOCIETY


Debra Malina, Ph.D., Editor

Beyond Belief — How People Feel about Taking Medications for Heart Disease

Lisa Rosenbaum, M.D.

"It's our job to help patients live as long as possible free of CVD complications. Although most patients share that goal, we don't always see the same pathways to get there. I want to believe that if patients knew what I know, they would take their medicine. What I've learned is that if I felt what they feel, I'd understand why they don't."

Rosenbaum, 2015




PERCEIVED TREATMENT INEFFICACY



Lack of tangible benefits contributes to discouragement and poor adherence

1. Polonsky WH. J Diabetes. 2015;7:777-778. 2. Polonsky WH, Skinner TC. Clin Diabetes. 2010;28(2):89-92.



Understanding and Addressing Problematic Adherence

Association Between Primary Care Practitioner Empathy and Risk of Cardiovascular Events and All-Cause Mortality Among Patients With Type 2 Diabetes: A Population-Based Prospective Cohort Study

Hajira Dambba-Miller, MRCGP, PhD^{4,3} Adina L. Feldman, PhD³ Ann Louise Kinmonth, FRCGP.

ABSTRACT

PURPOSE To examine the association between primary care practitioner (physician and nurse) empathy and incidence of cardiovascular disease (CVD) events and all-cause mortality among patients with type 2 diabetes.

Dambha-Miller et al, 2019

<section-header><section-header><section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>

HCP Empathy and Mortality Outcomes

- 10-year follow up of patients with newly diagnosed T2D:
- "those reporting better experiences of empathy in the first 12 months after diagnosis had a significantly lower risk
 (40% to 50%) of all-cause mortality over the subsequent 10 years vs. those who experienced low practitioner empathy."

Dambha-Miller et al, 2019

WHY DO PATIENTS FEEL THIS WAY?

- Threatening patients with medication
 - "If you can 't make some positive changes, then we'll have no choice but to put you on more medication, and perhaps even start insulin."
- Underlying messages
 - More medication should be avoided at all costs
 - You have failed
 - You are to be punished

SO WHAT TO DO?



SO WHAT TO DO?

1. Ask correctly

- "Any problems taking those medications?"

vs.

• "What's one thing about taking your medications that's been challenging?"

SO WHAT TO DO?



1. Ask correctly

2. Forgetfulness

- "Aside from forgetting, what else is tough about taking your meds?"
- Anchoring strategies

SO WHAT TO DO?

- 1. Ask correctly
- 2. Forgetfulness
- 3. Patient-provider trust and collaboration
 - Listen, listen, listen



SO WHAT TO DO?

- 1. Ask correctly
- 2. Forgetfulness
- 3. Patient-provider trust
- 4. Talk about beliefs about diabetes and medications




Challenging Harmful Beliefs

- 1. Taking your medications is one of the most powerful things you can do to positively affect your health
- 2. Your medications are working even if you can't feel it
- 3. Needing more medication isn't your fault
- 4. More medication doesn't mean you are sicker, less medication doesn't mean you are healthier
- 5. Emphasize the potential long-term gains

Diabetes and Your Health

"To live a long and healthy life, develop a chronic disease and take care of it."

- Sir William Osler



CONCLUSIONS


Poor medication adherence:

•... explains a great deal of the lack of glycemic progress over the past decade

•... is commonly an *attitudinal* issue, not just a behavioral issue.

•... is best addressed by considering the patient's perspective, and encouraging a two-way conversation about the perceived pro's and con's of the medication.

Thanks for Listening!



www.behavioraldiabetes.org


Lecture 2: 10:15 - 11:30 a.m. CDT


Jeremy H. Pettus, MD, Presents:


A Focus on Time in Range, Unmet Needs and Modern Management of Type 1 Diabetes


To Be Discussed...


- Incidence and pathophysiology
- Demographics of T1D in the U.S.
- A1c and time in range (TIR)
- Overview of pumps and CGM devices
- Interpreting CGM downloads in ~ 30 secs.
- Identifying and addressing common problems
- New insulin and glucagon formulations
- Advances in hybrid and closed AP



















	Risk of I	Developing 1	Type 1	vs Type	e 2
		General Population	0.3%	8-11%	
		If you have a sibling with T1D	4%	~30%	
		If your mother has T1D	2-3%	~30%	
		If your father has T1D	6-8%	~30%	
		If you have an identical twin with T1D	~50%	100%	
Edelman SV Fifth Edition	V. Taking control of your diabetes: a patient oriented book n Professional Communications Inc., Greenwich, CT. 544 p.	on diabetes. ages, 2017.			






























Options to Connect Directly to Smart Phone/Smart Watch

- Last 10 days
- No calibration
- No finger sticks
- Predictive low alert
- Medicare
 approved























Hybrid-Closed Loop System

- Auto-adjusts basal rate when in auto mode
- Target blood sugar: 120mg/dl
- · Mealtime boluses required
- Sensor (needs frequent calibration to stay in auto mode)




0 min	3:20 PM	3:20 PM	3:20 PM	Pod Age
Glucose	2	Eve	ntually	115 mg/dL
150				
125				
100				
75				
(5	3 PM 4 P	M 5PM	6 PM	7 PM
Active I	nsulin			2.28 U
3	-	-		
1	1			_
0	3 PM 4 P	M 5PM	6 PM	7 PM
	Delivery			O U Tota
6	dille			
1			_	
-1	3 PM 4 P	M 5PM	6 PM	7 PM
	arbohydra	ates		0 0
20				
10				


DIY Looping Hybrid Closed Loop NOT FDA Approved


- · Basal rate modulator
- Communicates with certain CGM devices (no calibration needed)
- Always in auto mode
- Still need to enter carbs and give correction doses


Smart Pens: Same Software Programs as Pumps




- I:Carb ratio
- Correction factor
- Insulin log
- Cloud-based












How Do you Know if the Basal Does is "Right"?


- Check blood sugar when there is no insulin boluses in the system and no carbohydrates from last meal (e.g. 2-4 AM) and compare to morning blood sugar
- Be on the lookout for variable bedtimes
- If <a>30mg/dL rise in glucose raise basal insulin dose
- If <u>></u>30mg/dL fall in glucose decrease basal insulin dose

ENDOCRINE SOCIETY












Case 1 Learning Points


- Type 1 diabetes does not require a midnight snack
- Nighttime highs SHOULD NOT reflex to increasing basal dose
- To determine if the issue is basal or bolus related, do "basal testing" as discussed
- Often, nighttime highs need to be addressed with more insulin before bed rather than changes to basal
- Newer basal insulins (Glargine U-300, Degludec U-00/U-200) are more consistent, have more flexible dosing, and less hypoglycemia


Case 2:		14 di	ays Wed	Apr 17, 2019 - Tue A	pr 30, 2019	
Amelia	5.7*	98	34	MODERATE	- 72%	Days with 93% CGM data 13 / 14 Avg. calibrations 0.1
 Amelia is a 57 yo female with Type 1 diabetes since age 2 	Glucose Management Indicator	mg/dL Average glucose (CGM)	mg/dL Standard deviation (CGM)	Hypoglycemia risk	21% 3% Time in range	per day Sensor usage
 Was told she needed tight glucose control to avoid complications 	Top Patterns	(2 ta averaged over 14 day	Amelia had a pat	l a pattern of night tern of significant lows betw est glucose day was data was in the Geget rang	een 5:20 AM and 6:00 AM	A. ABOVE HIGH THRESHOLD
 Has since had a fear of HyPERglycemia and prefers to "Ride low" 	(2180) (C 150) (C 160) (C 160)	1 · ·] · 3 6	• 1 • • 1 9 12t	man and a second	1 · · · · · · · · · · · · · · · · · · ·	12am
•Currently on insulin pump with CGM						






































To Be Discussed...


- Incidence and pathophysiology
- Demographics of T1D in the U.S.
- A1c and time in range (TIR)
- Overview of pumps and CGM devices
- Interpreting CGM downloads in ~ 30 secs.
- Identifying and addressing common problems
- New insulin and glucagon formulations
- Advances in hybrid and closed AP


Lecture 3: 12:00 – 1:30 p.m. CDT

Tricia Santos Cavaiola, MD, Presents:

Effective Use of Oral Medications for Type 2 Diabetes: Lowering Cardiovascular Risk While Improving Glycemic Control







Key Updates to the 2018 ADA/EASD Consensus Recommendations

General Recommendations

 In appropriate, high-risk individuals with T2D, decision to treat with GLP-1 RA or SGLT-2 inhibitor to reduce MACE, hHF, CV death or CKD progression should be considered independently of baseline A1c or A1c target

Dialectilogia https://doi.org/10.1007/s00125-019-02009-e CONSENSUS REPORT UPDATE

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) John B. Bune¹0 - Deborah J. Wester²¹⁰ - Apostolos Taspas¹0 - Peter Rossing¹⁴ - Getrude Mingrant Charad Mathew¹¹⁰0 - David A.D. Messo¹¹⁰ - Mathew¹¹⁰

 Providers should engage in shared decision making around initial combination therapy in new onset cases of T2D

GLP-1 RA Inhibitor Recommendations

- For patients with T2D and established ASCVD, where MACE is the gravest threat, the level of evidence for MACE benefit is greatest for GLP-1 RAs
- To reduce risk of MACE, GLP-1 RA can also be considered in patients with T2D without established CVD with indicators of high risk (>55 y/o with coronary, carotid, or LE artery sclerosis >50%, LVH, eGFR <60 ml/min/1.73, or albuminuria

(1)

Key Updates to the 2018 ADA/EASD Consensus Recommendations

Datestagia https://dx.arg/10.1007/n00125-010-05009-w CONSENSUS REPORT UPDATE


2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)


1


John B. Buse ¹0 • Deborah J. Wexler^{2,3} • Apostolos Tsapas⁴ • Peter Rossing^{3,4} • Geltrude Mingros Chantal Mathieu ¹⁰ • David A. D'Alessio ¹¹ • Melanie J. Davies ¹²


SGLT-2 Inhibitor Recommendations

- For patients with or without established ASCVD, but with HFrEF (EF <45%) or CKD (eGFR 30 to 60 ml/min/1.73 m2 or UACR >30mg/g, particularly UACR >300mg/g), the level of evidence for benefit is greatest for SGLT2 inhibitors
- SGLT2 inh. are recommended in patients with T2D and HF, particularly those with HFrEF, to reduce hHF, MACE and CV death
- SGLT2 inh. are recommended to prevent the progression of CKD, hHF, MACE and CV death in patients with T2D and CKD
- Patients with foot ulcers or at risk of amputations should only be treated with SGLT2 inh. after careful shared decision making around risks and benefits with comprehensive education on foot care and amputation prevention










What is the most likely reason why this patient has not achieved his A1c goal?

- A He needs prandial insulin
- B He needs a GLP-1RA
- c Poor adherence with his medication
- D His diabetes regimen is too complicated




Nine FDA-Approved Classes of Oral Meds for T<mark>2D</mark>

- Metformin (first line therapy unless contraindicated)
- Sulfonylureas, meglitinides
- Glitazones (pioglitazone, rosiglitazone)
- DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin)
- SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin , ertugliflozin)
- NEW ORAL GLP-1 Receptor Agonist (oral semaglutide)
- Bile acid sequestrant (colesevelam)*
- Dopamine receptor agonists (bromocriptine mesylate)*
- Alpha glucosidase inhibitors (acarbose, miglitol)*


* not discussed in detail in this presentation

http://www.fda.gov/drugs



Case 2: 69-year-old centrally obese female with T2D for nine years

- Medical history: Obesity (BMI 34 kg/m²), dyslipidemia, OSA, breast cancer s/p lumpectomy and hormonal therapy remission
- Family Hx: Both parents had type 2 diabetes
- Notes:
 - eGFR 75 mL/min/m², UACR normal (<30mg/g creatinine)
 –A1C 8.5%
 - -Diabetes therapy is metformin and a SFU
 - -LDL 121 mg/dL, triglycerides 266 mg/dL, HDL 39 mg/dL



Update on Metformin, SFUs, and TZDs (all generic)

Metformin

- eGFR <60 to <u>>45</u> OK to use full dose/monitor kidneys
- eGFR <45 to <u>></u>30 OK to use 50% maximum dose/monitor renal function every 3-6 months (PI says yearly)
- Check B-12 levels

SFU

- High secondary failure rate; however, when you stop them, the patient's A1c typically goes up
- Increase risk of hypoglycemia (elderly, CKD, CAD), weight gain

TZD (pioglitazone)


- Effective in prediabetes, best used early in the natural history (balance with potential side effects)
- Be cautious in combo with insulin (fluid retention)
- · Contraindicated in the setting of heart failure
- Weight gain
- Fracture risk is increased
- Risk of bladder cancer questionable, and the risk is low (~1/5000 in the general population)


Case 3: 56-year-old AA female diagnosed with type 2 diabetes at age 46

- PMH: HTN, dyslipidemia, obesity and NAFLD (non alcoholic fatty liver disease)
- A1C 9.2% on maximum doses of metformin and SFU
- Occasional mild hypoglycemia
- No home glucose monitoring data
- eGFR 50 mL/min/m², BMI 51 kg/m²
- BP normally above 140/90 mmHg; on no HTN meds


What therapeutic intervention would you change/initiate if you were evaluating this patient, once you have confirmed she is adherent with her medications?

- A Add pioglitazone
- B Add a DPP-4 inh.
- **c** Add a SGLT-2 inh.
- D Add a GLP-1 RA
- E Combination of a DPP-4 inh & SGLT-2 inh.





Mechanism of Action	Inhibit the enzyme, DPP-4, that normally inactivates GLP-1 and other incretins within minutes
Benefits	 Once daily oral administration Virtually no side effects Can be added to any diabetes drug except GLP-1 RAs A1c reduction ~ 0.5-1% range (depends on baseline A1c)
Concerns	 Dose adjustment with renal insufficiency (only for sita-, saxa- and alogliptin), not for linagliptin Warnings and precautions: pancreatitis, heart failure, acute renal failure, angioedema, Stevens-Johnson, severe arthralgia, bullous pemphigoid
Clinical Pearls	 Efficacy of the DPP-4 inhibitors is similar All DPP-4 inhibitors come in combination pill with metformin (Alo- is combined with Pio- and Lina- is combined with empa-; new metformin XR, saxa-, dapa- tablet approved)



	Generic Name	Trade Name
DPP-4 Inh.	Alogliptin	Nesina
	Linagliptin	Tradjenta
	Saxagliptin	Onglyza
	Sitagliptin	Januvia

Combination Pills with a DPP-4 Inhibitor

Generic Name	Trade Name	Daily Dose Range	Recommended
		(mg)	Frequency
Sitagliptin/metformin	Janumet	50/500, 50/1000	Twice with meals
Saxagliptin/metformin ER	Kombiglyze XR	5/500, 2.5/1000, 5/1000	Once daily with evening meal
Linagliptin/metformin	Jentadueto	2.5/500, 2.5/850, 2.5/1000	Twice with meals
Linagliptin/empagliflozin	Glyxambi	5/10, 5/25	Once daily
Dapagliflozin/saxagliptin	Qtern	10 mg/5mg	Once daily
Alogliptin/pioglitazone	Oseni	25/15, 25/30, 25/45, 12.5/15, 12.5/30, 12.5/45	Once daily
Alogliptin/metformin	Kazano	12.5/500, 12.5 mg/1000	Twice with meals
Ertugliflozin/sitagliptin	Steglujan	5/100, 15, 100	Once daily
Saxagliptin/dapagliflozin/ metformin XR	Qternmet XR	2.5/2.5/1000, 2.5/5/1000, 5/5/1000, 5/10/1000	Once daily

Newest triple combination: Empagliflozin/linagliptin/metformin (Trijardy XR)

Case 4: 70-year-old obese female with T2D for 25 years

- A1C 8.4% on maximum doses of metformin, a SFU, and a DPP-4 inh.
- Medical Hx: HTN, arthritis, recent admission for CHF
- Family Hx: Type 2 diabetes and obesity (both parents)
- Notes:
 - Fearful of injections and gaining weight BMI 31 kg/m²
 - HTN, osteoporosis, and CKD 3A (eGFR 58 mL/min/m²)
 - Home glucose monitoring shows FBS (147-219 mg/dL) with a few post dinner values (188 to 275 mg/dL)

How would you treat this patient to lower her A1c?

- A Add a TZD
- B Add a SGLT-2 inh. (cana-, dapa-, empa-, ertugliflozin)
- **c** Try to convince her to add a GLP-1 RA (exena-, liraglu-, dulaglu-, semaglutide
- **D** Try to convince her to add a basal insulin at bedtime


Case 4 Continued


- Low dose SGLT-2i was added to her regimen and then titrated to the maximum dose after one month
- A1C dropped to 7.3% (baseline 8.4%) and she lost 15 lbs
- She experienced a yeast infection which was easily treated with oral fluconazole and she did not want to stop the SGLT2i
- LDL-C increased from 100 to 108 mg/dL (8% rise), HDL-C increased 10%, and her TGs decreased by 25%


Mechanism of Action	Reduce renal glucose reabsorption and increases urinary glucose excretion
Benefits	No hypoglycemia (except when being used with SFU or insulin) Mean A1c reduction ~ 1% (starting from a baseline A1c of ~8.0%) Weight loss (2-5% of body weight) and systolic BP reduction (2-6mmHg)
Concerns	 Genital mycotic infections. In women (6 to 12% higher than comparator) and in uncircumcised males (2 to 6% higher than comparator) Hypotension secondary to volume contraction especially in the elderly, those on loop diuretic use and in patients with reduced renal function. 4 to 8% elevation in LDL cholesterol (TGs goes down and HDL goes up) Assess renal function (discussed later) New label warnings : DKA (discussed later), risk of amputation (discussed later), bone fractures, Fournier's Gangrene, acute kidney injury, UTI
Clinical Pearls	•Cana now approved for renal protection and can be used with a eGFR down to 30 •Empa- Dapa-and canagliflozin showed positive CVD outcome trials (discussed later) •Can be added to any other oral agent or injectable
r caris	 Tell women to practice good hygiene and look out for yeast infections (may want to suggest to have some anti yeast infection medication at home such as miconazole)


Generic Name	Trade Name
Canagliflozin	Invokana
Dapagliflozin	Farxiga
	Jardiance
	Steglatro
daily before first meal of day (aCEP)	AF ml/min/with CKD can use to a cCEP of
daily before first meal of day (eGFR	>45 mL/min//with CKD can use to a eGFR of
ing 100 mg daily and eGFR > 60 mL/	min
0	,
g and need additional glycemic contr	ol
ning with or without food (eGFR>45 n	


- Increase to 25 mg daily if tolerating and need additional glycemic control (eGFR>45 mL/min) Ertugliflozin:
- Starting dose: 5 mg daily in morning with or without food (eGFR for both doses >60 mL/min)
- Increase to 15 mg daily if tolerating and need additional glycemic control











Blood Pressure Management

Individualize BP Goals:

<140/90 mmHg (10-yr CV risk <15%)


<130/80 mmHg (10-yr CV risk >15%)

Diabetes Care Volume 43, Supplement 1, January 2020, S111-S134

Dyslipidemia Management

Individualize lipid Goals:

LDL< 100mg/dl in all PWD LDL<70 mg/dl if ASCVD present Triglycerides less than 200mg/dl HDL as high as you can get it!





Management Of Hypertriglyceridemia

- 1. Elevated triglycerides combined with low HDL levels are part of the insulin resistant state and metabolic syndrome.
- 2. Diet, exercise and improved glycemic control will improve but not typically normalize elevated TG levels in type 2 DM.
- 3. The goal is to get the TGs to below 200mg/dl, which in term will elevate the HDL levels
- 4. Fibric acid derivatives such as fenofibrate are commonly used to treat high TGs.
- 5. Icosapent ethyl is an omega-3 fatty acid that has the formal indication from the FDA to reduce heart attacks and strokes in patient who have or are at risk for ASCVD.

N Engl J Med 2019; 380:11-22 reduce it trial

Non-Insulin CVOTs in T2D: DPP-4 Inhibitors					
Study	SAVOR	EXAMINE	TECOS	CAROLINA	CARMELINA
DPP4-i	saxagliptin	alogliptin	sitagliptin	linagliptin	linagliptin
Comparator	placebo	placebo	placebo	sulforviurea	placebo
Ν	16,500 NEUTRAL	5.40 RAL	14,000 AL	6 PRAL	placebo NEUTRAL 2017
Results	NE13	NE 2013	NE 2015	NE2017	2017





Diabetes Medications FDA Approved for CV Risk Reduction

Empagliflozin (based on EMPA-REG data)

to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Liraglutide (based on LEADER data)

to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established CV

Canagliflozin (based on CANVAS program data)


 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease


Semaglutide (based on SUSTAIN 6)

the indication of reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease (CVD).

Dulaglutide (based on REWIND data)

for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors.







- Glycemic targets and glucose-lowering therapies should be individualized
- Diet, exercise, and diabetes self-management education and support are the foundations of therapy
- Unless contraindicated, metformin is the preferred first line drug
- After metformin, the first consideration is whether the patient has established ASCVD or CKD. If not, then whether hypoglycemia, weight or financial status are dominant issues. Shared decision making is KEY!


Key Principles of Management of T2D

- GLP-1 RA are the preferred first injectable therapy over basal insulin except patients with very poor glycemia control
- Many patients over time will require insulin therapy alone or in combination with other agents to maintain glycemic control
- Vascular disease is the most common cause of death and prevention strategies need to be emphasized (A1c, aspirin, blood pressure, cholesterol, smoking cessation, and diabetes drugs that reduce ASCVD/heart failure)

Lecture 4: 2:00 – 3:15 p.m. CDT

Steven V. Edelman, MD, Presents:

Practical Application of Injectable Agents and Their Cardiovascular Effects: Individualized Treatment Strategies




Case 1: 54 year old male with type 2 diabetes for 10 years


- o History of dyslipidemia, hypertension, NAFLD
- Strong family history of type 2 diabetes
- o Currently on metformin, SFU and a DPP4 inhibitor
- Recent myocardial infarction s/p 4 cardiac stent insertions
- o A1c 9.3%
- \circ Creatinine 1.3 eGFR 70
- HGM data: ranges from 82 to 379 mg/dl
- Bedtime average 210 mg/dl SD 76mg/dl
- Morning average 221 mg/dl

Which of the following would you recommend for this patient?

A	Initiate basal insulin	
В	Initiate a GLP-1 Receptor Agonist (RA)	
С	Initiate premixed insulin (70/30) BID	
D	Initiate a fixed combination of a basal insulin and a GLP-1RA	
L		




Basal Insulin v	(an incretin hormone)
Insulin: Injected once or twice a day	GLP-1 RA: Injectable once or twice a day, injectable once weekly, or oral once daily
Need to titrate dose to achieve the desired FBS	Titrate to the highest acceptable dose to avoid nausea
Need to institute home glucose monitoring (SMBG)	"No" need for SMBG
Important to have frequent follow up when initiating basal insulin (days to weeks)	Follow up not as crucial
Weight gain	Weight loss
Hypoglycemia	No Hypoglycemia





Mechanism of Action	Mimic the effects of human GLP-1
Benefits	 Significant A1c reductions (1.0 to 3.0% depending on baseline) Shorter acting GLP-1 RAs have greater effects on PPG Weight loss No hypoglycemia Once daily, twice daily and once weekly formulations
Concerns	 GI side effects (typically nausea) Contraindicated in patients with a personal or family history of MTC or MEN2 Relative contraindication in patients with a history of pancreatitis (important to know the etiology)
Clinical Pearls	 Ideal choice in obese patients with poor control, especially those on large doses of insulin "No" need to initiate or increase glucose testing Several with positive CVOT results

	Generic Name	Trade Name	
GLP-1 Receptor	Exenatide		
Agonists	Twice-daily	Byetta	
	Once-weekly	Bydureon	
	Liraglutide		
	Once-daily	Victoza	
	Dulaglutide		
	Once-weekly	Trulicity	
	Lixisenatide		
	Once-daily	Adlyxin	
	Semaglutide		
	Once weekly	Ozempic	
	Oral Semaglutide	Rybelsus	
	Once daily	TCO	

	Generic Name	Trade Name
Basal Insulin/GLP-1 Receptor Agonist Fixed Combination	Glargine/lixisenatide once daily Degludec/liraglutide once-daily	Soliqua Xultophy









Case 2: 72 year old Caucasian woman with type 2 diabetes for 23 years


- On maximal doses of metformin, SU, and a SGLT-2 inhibitor
- She adamantly does not want to take insulin for fear of weight gain
- PMH: dyslipidemia, hypertension, papillary thyroid cancer and obesity (BMI=31)
- Both parents and two siblings have type 2 diabetes and early CVD
- o eGFR 65 ml/min
- Her A1c is 8.8 % (goal for this patient at least less than 8%)
- Average FBS is in the 180s (does not test at other times)

What would you recommend now for this patient?


Α	Start a DPP4 inhibitor	
В	Try to convince her to start basal insulin and titrate the dose to get her FBS less than 140mg/dl	
С	Start a GLP1-RA	
D	Initiate a fixed combination of a basal insulin and a GLP-1RA	









Pen dose steps (units): insulin	Pen dose steps (units): insulin
degludec + liraglutide	glargine + lixisenatide
10 dose steps=10 units insulin degludec +0.36 mgs of liraglutide	15 dose steps=15 units insulin glargine + 5 mcg of lixisenatide
50 dose steps=50 units insulin degludec +1.8 mgs of liraglutide	30 dose steps=30 units insulin glargine + 10 mcg of lixisenatide
	60 dose steps=60 units insulin glargine + 20 mcg of lixisenatide
Starting dose:	Starting dose:
16 dose steps which has 16 units insulin	If glargine U-100 dose is <30, start at 15 dose
degludec + 0.58 mgs of liraglutide	steps which has 15u glargine + 5mcg lixi
	lf glargine U-100 dose is >30, start at 30 dose steps which has 30u glargine + 10 mcg lixi
Titrate according to FBG, as if you were using basal insulin alone, generally 2 dose steps at a time, usually every 3-4 days	Titrate according to FBG, as if you were using basal insulin alone, generally 2-4 dose steps at a time, usually weekly
Maximum dose is 50 units of insulin degludec and 1.8 mgs of liraglutide	Maximum dose is 60 units of insulin glargine and 20 mcgs of lixisenatide








Effects of insulin degludec/liraglutide in patients with poorly controlled type 2 diabetes with HbA1c >9%: analyses from the DUAL program




Frias JP et al. Diabetes 2018 Jul; 67(Supplement 1): - . https://doi.org/10.2337/db18-1092-P











	Generic Name	Trade Name
Fast-Acting Insulin	regular	Humulin R, Novolin R
	U-500 regular	Humulin R U-500
	aspart	NovoLog
	faster acting aspart	Fiasp
	glulisine	Apidra
	lispro (U-100 and U-200)	Humalog
	Follow on biologic lispro	Admelog
	inhaled insulin	Afrezza
Basal Insulin	intermediate-acting:	Humulin N
	NPH	Novolin NPH
	long-acting:	
	detemir	Levemir
	glargine (U-100)	Lantus
	glargine (U-300)	Toujeo
	degludec (U-100/200)	Tresiba






d	agnosed	with type	e 2 diabe	tes 9 yeai	rs ago	
0	Currently on maximum doses of 3 oral agents: metformin 1000 mg BID, SFU and a SGLT2 inhibitor. She was intolerant to GLP-1RAs.					
0				the morning. Aft and she stopped i		
0	A1c > 8.5% for	the past 2 years	, eGFR 89, LFT	s normal		
0	○ Current SMBG (mg/dl) below:					
		Pre-Breakfast	Pre-Lunch	Pre-Dinner	Bedtime	
Mon	day	211			185	
Tues	sday	247		174		
Wec	Inesday	181			196	
Thu	rsday	226		179		
	- J			-		

Which of the following is the single most likely explanation for her failure with basal insulin:

Α	Poor adherence	
В	Initial dose was too little	
С	Inadequate titration of the glargine U-100	
D	Glargine U-100 should have been given at bedtime	

<section-header><text><text><text><text><text><text><text><text><text><text><text>



Case 4: 55 year old obese Latino male with a 22 year history of type 2 diabetes


- o CKD stage 3b (eGFR 37 ml/min)
- o History of ASCVD s/p MI and CHF
- $\circ~$ HTN, dyslidemia, OSA , NAFLD and h/o pancreatitis
- Currently treated with low dose metformin, SFU, DPP4 inhibitor and canafliflozin (initiated by nephrology)
- A1c 8.9%

Time	Blood glucose range	Blood glucose average	
Pre-Breakfast	148 – 229 mg/dL	(175 mg/dL)	
Pre- Lunch	111 – 182 mg/dL	(147 mg/dL)	
Pre- Dinner	91 – 155 mg/dL	(139 mg/dL)	
Bedtime	148 – 231 mg/dL	(184 mg/dL)	
No reports of hypoglycemia			

Whi	Which of the following would you suggest for this patient?				
	Α	Initiate pioglitazone			
	В	Initiate basal insulin			
	С	Start a GLP-1 RA and stop his DPP-4 inhibitor			
	D	Change to a different SGLT-2 Inhibitor			


 Insulin o 10 weel 	degludec U-200 wa	as added at night (20 units)	and titrated up to 120 units over the nex	×t
• He was	asked to test 2x/d	ay (pre-breakfast and bedtir e the patient is not going to		
-	Pre-Breakfast	82 – 155 mg/dL	(~122 mg/dL)	
	Pre- Lunch			
	Pre- Dinner			
	Bedtime	128 – 183 mg/dL	(~155 mg/dL)	
mon o Oral durii	nths l agents can	be continued unles which case the su	emia. Gained 2 lbs in 3 s hypoglycemia occurs Ilfonylurea should be	


C	Clinical Pearls: ombination Therapy with Basal Insulin
1	Start with 10 to 20 units (based on FBS, weight)
2	The key to success is frequent follow up after initiation to avoid "failure" (most patients will need 40 to 70 units/day)
3	Have the patient follow a self-titration regimen and return to clinic or follow up in some other manner (phone, fax, email, telehealth, etc.) <u>relatively soon</u>
4	You can usually limit SMBG to only once a day in the morning but check at bedtime once in awhile to make sure the pt. does not need pre dinner fast acting insulin.
	Diagnosis and management of type 2 diabetes. al Communications, Inc., Greenwich, CT. 288 pages, 2014.




3. Other options include prandial insulin or a GLP-1 RA.

Edelman SV, Henry RR. Diagnosis and management of type 2 diabetes. 12th Edition. Professional Communications, Inc., Greenwich, CT. 288 pages, 2014.







Summary
 GLP-1 RAs represent a tremendous advance in the treatment of type 2 because of significant glucose lowering in addition to weight loss and reducing the risk of hypoglycemia
 Combination therapy (adding basal insulin to daytime OHAs/GLP1-RAs) is safe, effective and easy to implement
 The fixed combination of basal insulin and a GLP-1 RA has clinical advantages in terms of efficacy, reduced side effects and ease of use
 The Basal Bolus approach in type 2 diabetes does not need to be four injections per day (pens, patch pumps and inhaled insulin to improve adherence)
• Adherence and persistence needs to be addressed at every visit
 Protection for ASCVD